In the Market

In the Market features articles regarding recent trends in biotechnology and medical devices that influence the selection and performance of SanaCurrents catalysts.

Buyout candidates thrive, rare disease drug candidates dive

Companies with mature science such as kinase inhibitors and “zombie” biotechs – public companies that remain listed despite numerous failures – rarely thrive in the biopharma M&A market. Bidders typically…

Bids for Verona (VRNA), Monogram (MGRM) may signal new life for M&A

If the buyout market signals biotech and medtech are rebounding in the midst of RFK Jr. and Trump II, two deals in the past week present convincing evidence. One was…

AstraZeneca snaps up Fusion for $2.4 billion

Some market buzz hits the mark even when it is the worst-kept secret on the street. AstraZeneca (NASDAQ:AZN) on March 19 agreed to buy Fusion Pharmaceuticals, Inc. (NASDAQ:FUSN). AstraZeneca moved…

Coya Therapeutics (COYA) reports positive biomarker data in ALS

Coya Therapeutics (NASDAQ:COYA) recently published confirmatory analyses of blood biomarker data from a cross sectional cohort of sporadic Amyotrophic lateral sclerosis (ALS) patients (n=30) and healthy controls (n=10) who participated…

‘Picture-perfect’ phase III data pushes Crinetics’ (CRNX) shares up 63%

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) said on September 10, 2023, its lead drug paltusotine, a once-a-day oral treatment for the rare disease acromegaly, met the primary and secondary endpoints in a phase…

Will sickle cell drug reach patients?

The ground-breaking allure of CRISPR science attracted billions to biotech companies since the technology emerged a dozen years ago. This December, the first CRISPR treatment may reach the commercial marketplace…

Cardiff’s (CRDF) shares soar on new onvansertib deal with Pfizer

After the market closed on August 7, 2023, Cardiff Oncology, Inc. (NASDAQ:CRDF) said it had expanded its partnership with Pfizer, Inc. (NYSE:PFE) to advance Cardiff’s lead program onvansertib as a…

FDA approval for Tarsus’ (TARS) eye drug yields big gain on SanaCurrents catalyst

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) said before the market opened on July 25, 2023, the FDA approved its lotilaner ophthalmic solution to treat Demodex blepharitis, making the drug the first and…

SanaCurrents closing coverage on Verrica (VRCA), Viridian (VRDN)

Shares of Verrica Pharmaceuticals, Inc. (VRCA) rose sharply this week ahead of the company’s July 23, 2023, PDUFA date for VP-102, a topical combination drug-device product. VP-102 would be the…

SanaCurrents discontinuing coverage of Summit Therapeutics

Summit Therapeutics, Inc., a long hold within the SanaCurrents portfolio, this year made progress towards advancing ivonescimab in a phase III trial for non-small cell lung cancer (NSCLC). While the…

NEWER POSTS

OLDER POSTS